Order Toll Free: 1-888-848-1945. You save an additional 20% by ordering online.

Welcome! Log in:

Forgot password?
Do I need an account to order?
River Professional Group - Your Neighborhood Drugstore Online

Frequently Asked Questions

Do you carry Acomplia (Rimoslim, Riobant, Slimona, Zimulti)?

Short Answer

Rimonabant, the active ingredient in Acomplia, is no longer available.

Long Answer

Acomplia (also known as Rimonabant, Rimoslim, Riobant, Slimona, SR141716, and Zimulti) is a drug prescribed in combination with diet and exercise for weight loss in obese or overweight patients with Type 2 diabetes or dyslipidaemia (abnormal blood lipid levels). The generic name of this drug is rimonabant. It has been approved for use in the European Union, India, Brazil and Mexico. 

Rimonabant was developed for both weight loss and smoking cessation; however, it has only been approved for weight loss in the countries that market it. Rimonabant is the first in a new class of drugs called selective cannabinoid-1 receptor blockers (CB1). It works on the body's endocannabinoid system which is responsible for regulating weight, energy balance, glucose, and lipids (fats in the blood). In clinical studies, rimonabant was found to reduce blood glucose levels and raise the levels of "good" cholesterol by more than what could be accounted for by the weight loss alone.

The most common side effects reported in clinical trials were dizziness, nausea, headaches and diarrhea but these effects were temporary. Depression and anxiety were reported in independent studies.

Rimonabant should not be used by patients with liver or kidney impairment. It should be used with caution when taking CYP3A4 inhibitors; e.g., ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, and nefazodone. Because it contains lactose, it should be avoided by those who are lactose-intolerant or have difficulty with lactose absorption. Due to the incidence of depression reported in some studies, patients with uncontrolled psychiatric illnesses such as major depression or psychosis should not take this medicine. As with any medication, please consult your doctor before taking rimonabant.

European Trade Name:
India Trade Names:
Slimona, Rimoslim
Brazil Trade Name:
USA Trade Name: (if approved by the FDA)

Additional Information

Rimonabant: From Wikipedia, the free encyclopedia
Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m, or patients wih a BMI greater than 27 kg/m with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK, it has been available since the end of July 2006. As of 2007, the drug was available in 38 countries.
New diabetes drug Rimonabant again proves to be a good option
This article discusses the results of a drug trial involving 278 diabetes patients.
Rimonabant Helps With Weight Loss and Smoking Cessation
The results of two early rimonabant trials for smokers and for overweight or obese patients with blood lipid disorders.
Anti-obesity drug no magic bullet
Canadian doctors are concerned about unrealistic expectations of rimonabant.